Introduction
Trichosporon spp. are opportunistic basidiomycetous emerging yeast pathogens. The classifi cation of the genus Trichosporon was revised in 1992 by Gu é ho et al . [1] , and presently includes 38 species [2] . Invasive infections caused by Trichosporon spp. are frequently catheterrelated [3 -5] . In some studies [6 -8] the members of the genus are the second most common cause of disseminated yeast-infections, just after those caused by Candida species. Moreover trichosporonosis is associated with high mortality rates [3,6 -11] . Over the past fi ve years, Trichosporon spp. were isolated at Bordeaux University Hospital from non blood samples of patients at risk of invasive fungal infections. However, the case presented here is the sole disseminated trichosporonosis among 342 episodes of yeast blood infections diagnosed during the same period. DNA amplifi cation of the ribosomal Internal Transcribed Spacers (ITS) and of part of the 18S rDNA and nucleotide sequencing allowed identifi cation of Trichosporon loubieri . To our knowledge, this is the third reported case of human invasive trichosporonosis due to this fungus. liver failures. An empirical therapy with intravenous imipenem and vancomycin was introduced, but apyrexia was only obtained with adjunctive corticotherapy. The patient left the hospital a few days later with amoxicillin, ofl oxacin, and prednisolone.
A new episode of febrile pancytopenia (40 ° C) on 23 November 2007 required further hospitalization. Valaciclovir, ceftazidime, amikacin, and liposomal amphotericin B (LAmB) 3 mg/kg/day were administered. Blood immunophenotyping revealed 47% blastic cells. On 26 November two blood cultures, inoculated the day before on aerobic and fungal media (Mycosis Bactec, Becton-Dickinson, United States), yielded fungi (12 other fl asks taken later remained negative). Intravenous caspofungin (70 mg/day) was added to the initial treatment. Subcultures of the isolates on Sabouraud-Chloramphenicol-Gentamicin (BectonDickinson) and CHROMagar (Becton-Dickinson) media showed white, mat, and dry colonies with sharp radial fi ssures (Fig. 1a) .
Urease turned positive in 12 hours and an AUXA-COLOR ® 2 gallery (Biorad, France) indicated the fungus to be Trichosporon spp. Growth on 2% malt extract agar under cover slide revealed hypha with arthroconidia, blastoconidia, and typical fusiform giant cells (Fig. 1b) , as described by Gu é ho and co-workers [12] . Caspofungin and LAmB were stopped (28 November) and intravenous voriconazole was administered (600 mg/kg/day for the fi rst 48 hours, then 400 mg/kg/day).
Identifi cation was unsuccessful using ID 32C ® (bioMerieux, France), as the code, 7777776275, indicated
Cryptococcus laurentii (57.4%), Cryptococcus humicola (29.7%), or Trichosporon mucoides (12.9%).
Antifungal susceptibility was investigated using E-test ® (bioM é rieux). The minimal inhibitory concentrations (MICs) were: amphotericin B, 0.38 μ g/ml; 5-fl uorocytosine, 3 μ g/ml; fl uconazole, 16 μ g/ml; voriconazole, 0.5 μ g/ml; posaconazole, 0.4 μ g/ml; and caspofungin Ͼ 32 μ g/ml.
Liver function began to decline on 29 November. EBV, CMV, HSV, human herpes virus 6, and parvovirus B19 DNA detection remained negative in blood and secretions. The next day, a multidisciplinary committee decided to gradually stop the treatment, given the severity of the underlying illness and the rapidly degenerating clinical state of the patient. Voriconazole was stopped on 6 December and the patient died two days later.
Final identifi cation of the fungal isolate was obtained after sequencing the ITS region and an 18S segment of rDNA gene using universal fungal primer pairs ITS1/ITS4 and NS3/NS4 [13 -16] . DNA was extracted from 1. Discussion Girmenia et al . [10] published the largest retrospective multicentric study on invasive trichosporonosis in the literature, including 287 cases, although identifi cation to the species level was done only for 30 isolates. Most cases of trichosporonosis were reported in immunosuppressed patients, with the major predisposing factor being haematological malignancy (62.8%), most frequently acute leukemia (68%) and lymphoma (10.6%). Among those patients with haematological diseases, 43% received conventional amphotericin B (AmB), 2% lipid formulation of AmB, and 27% a combination of antifungals including AmB. Fluconazole monotherapy was only used in 2.2% of cases, and AmB plus fl uconazole or itraconazole in 7%. Azoles were rarely administered, but seemed to be correlated with better survival rates, from 44 to 50%, but no patient was treated with voriconazole. The overall mortality rate attained 77%.
Trichosporon loubieri was initially isolated from a cow mastitis. Only two human cases of invasive infection caused by this fungus have been described [15, 18] with both patients being older than the one in our study (45 and 56 versus 21 years old). The fi rst case involved a renal infection in a patient with polycystic kidney disease, but no fungemia was documented [18] . Nephrectomy, intravenous AmB with adjunctive oral itraconazole for 6 weeks, and a kidney transplant were combined to cure the patient. Marty et al . also described a fatal disseminated trichosporonosis in a patient with haematological malignancy, but the infection occurred earlier in the progress of the underlying disease [15] . Splenectomy and high-dose intravenous fl uconazole (800 mg/kg/day) led to stabilization of the hepatic lesions. The patient fi nally died 4 months after the initial diagnosis.
Trichosporon spp. are resistant to echinocandins [3,19 -22] and AmB resistance is also frequently reported for Trichosporon asahii , Trichosporon coremiiforme , and Trichosporon faecale [19 -25] . The present isolate of T. loubieri was susceptible in vitro to AmB, with a MIC of 0.38 μ g/ml, whereas the AmB MIC of the Marty et al . isolate was higher (2 μ g/ml) [15] . Triazoles have the highest activity against Trichosporon species, especially the new generation antifungals, i.e., voriconazole, posaconazole, ravuconazole and isavuconazole [19,21 -23,26,27] . This is the reason why, in this case, once the genus Trichosporon was diagnosed, voriconazole therapy was started.
Interestingly, unequivocal identifi cation to the species level could only be achieved with molecular tools, as was the situation with the two other isolates involved in human invasive infection (cases reported by Padhye et al . [18] and Marty et al . [15] ). Trichosporon species are indeed diffi cult to identify in the routine laboratory. However , some characteristics separate T. loubieri from other species [1, 12] , i.e., (i) its ability to grow up to 42 ° C, (ii) its very high rate of growth (40 -45 mm diameter colonies in 10 days at 22 ° C on Sabouraud glucose agar), and (iii) its fusiform giant cells on 2% malt extract agar under a cover slide. Gu é ho et al . [1, 12] gallery (bioM é rieux) , for the present isolate were different to those described by Marty et al . (viz. lactate, D-mannitol, D-sorbitol, L-rhamnose, erythritol, glucuronate, and D-melezitose) [15]. In addition, there were differences in three of the tests between our isolate and the consensus profi le (glycerol, glucuronate, and D-melezitose) [1, 12] . While there were no clear differences between the present strain and those described by Padhye et al ., intrinsic variations between assimilation profi les of the two isolates described in their study should be noted [18] . On the other hand, the different strains of T. loubieri could only be distinguished from T. asahii and T. inkin by their ability to grow on D-melibiose (Table  1) . No test was able to defi nitely discriminate T. loubieri from T. mucoides . Accordingly, commercial yeast identification galleries are not appropriate for the identifi cation of T. loubieri . As its identifi cation to the species level requires molecular methods, the presence of T. loubieri may have been previously under-estimated in clinical practice.
